Agenus Inc. (AGEN)
| Market Cap | 294.21M +139.8% |
| Revenue (ttm) | 132.69M +30.5% |
| Net Income | 91.80M |
| EPS | 2.51 |
| Shares Out | 45.02M |
| PE Ratio | 2.61 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 295,785 |
| Open | 6.85 |
| Previous Close | 6.84 |
| Day's Range | 6.43 - 6.86 |
| 52-Week Range | 2.71 - 10.31 |
| Beta | 1.52 |
| Analysts | Strong Buy |
| Price Target | 26.33 (+302.91%) |
| Earnings Date | Nov 5, 2026 |
About AGEN
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte ... [Read more]
Financial Performance
In 2025, Agenus's revenue was $114.20 million, an increase of 10.37% compared to the previous year's $103.46 million. Losses were -$101,000, -99.96% less than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for AGEN stock is "Strong Buy." The 12-month stock price target is $26.33, which is an increase of 302.91% from the latest price.
News
Agenus’ neoadjuvant BOT+BAL meets primary endpoint in Phase 2 colon cancer trial
Agenus (AGEN) announced the peer-reviewed publication of results from the Phase 2 UNICORN trial evaluating short-course preoperative, or neoadjuvant, botensilimab – BOT -, Agenus’ anti-CTLA-4 antibody...
Agenus Announces Nature Medicine Publication of Multicenter UNICORN Phase 2 Trial Demonstrating Deep Responses with Neoadjuvant BOT+BAL in Resectable Colon Cancer
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AGEN--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the peer-reviewed publication of results from the investigator-sp...
Agenus announces Phase 2 results from cohort of NEOASIS
Agenus (AGEN) announced early Phase 2 results from the mismatch repair-deficient colon cancer cohort of NEOASIS. NEOASIS is evaluating botensilimab, Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 an...
Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AGEN--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced early Phase 2 results from the mismatch repair-deficient (dMMR) c...
Agenus to Provide Third Quarter 2026 Financial Report and Development Update
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AGEN--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the Company will release its third quarter 2026 f...
Agenus Transcript: Chardan's 10th Annual Healthcare Conference
The strategic focus moved to Phase III ROBBIN in neoadjuvant MSS colon cancer, with first enrollment expected in Q1 2027 and a pathologic response interim in Q4 2027. Armenia authorization and access programs provide additional routes to treatment.
Agenus to Participate in Chardan's 10th Annual Healthcare Investor Conference
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #Botensilimab--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that Zack Armen, Head of Corporate Development and Invest...
Agenus announces Armenia granted marketing authorizations for BOT+BAL
Agenus (AGEN) announced that the Ministry of Health of the Republic of Armenia has granted marketing authorizations for Botvymo, BOT, and Evamplix, BAL, each approved for use in combination with…
Armenia Grants First Marketing Authorizations for Agenus' BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #Armenia--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the Ministry of Health of the Republic of Armenia has gra...
Agenus announces 3-year follow-up results from Phase 1b C-800-01 trial
Agenus (AGEN) announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab, Agenus’ multifunctional, Fc-enhanced ...
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AGEN--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of it...
Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOT--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that two posters highlighting research on botensilimab (BOT), an F...
Agenus initiated with a Buy at Rodman & Renshaw
Rodman & Renshaw initiated coverage of Agenus (AGEN) with a Buy rating and $19 price target The firm cites the potential for botensilimab plus balstilimab to establish a new perioperative…
Agenus initiated with a Buy at Chardan
Chardan initiated coverage of Agenus (AGEN) with a Buy rating and $40 price target The firm views Agenus as a “positively asymmetric immuno-oncology story.” The company is centered on its…
Agenus files to sell 221,525 shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 221,525 shares of common stock. The company is not selling any…
Agenus Registration statement: Registration filing
Agenus filed a registration statement on September 11, 2026, providing details about a securities offering with the SEC.
Agenus Transcript: Investor update
ROBBIN phase III neoadjuvant trial is progressing globally, with strong physician and investigator interest driven by durable BOT+BAL responses and expanding access programs. The study aims to reduce recurrences and chemotherapy needs in high-risk colon cancer, with robust infrastructure and product supply supporting rapid execution.
Agenus Slides: Investor update
Agenus has posted slides in relation to its latest quarterly earnings report, which was published on September 10, 2026.
Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that a poster evaluating botensilimab (BOT), an Fc-enhanced multifunctional anti-...
Agenus Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
BOT/BAL combination therapy has shown strong efficacy in MSS colon cancer, with phase III trials underway and robust financing secured. The addressable market exceeds $7B, and upcoming milestones include key trial readouts and data presentations.
Agenus to Participate in Upcoming September Investor Conferences
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOT--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that Robin Taylor, Ph.D., Chief Commercial Officer, and Zack Armen...
Agenus Announces Peer-Reviewed Publication Linking BOT+BAL's Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the peer-reviewed publication of mature Phase 1b results from the fully enrolled ...
Agenus: No colorectal cancer recurrences observed at updated follow-up in trial
Agenus (AGEN) announced the peer-reviewed publication of updated results from the investigator-sponsored Phase 2 NEST trial evaluating neoadjuvant botensilimab, Agenus’ multifunctional, Fc-enhanced an...
Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOT--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the peer-reviewed publication of updated results from the investig...
Agenus price target lowered to $25 from $30 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Agenus (AGEN) to $25 from $30 and keeps a Buy rating on the shares. The firm assumes the company will issue 23M…